Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds

Date:
November 16, 2021
Source:
Johns Hopkins University Bloomberg School of Public Health
Summary:
A study of more than 200,000 U.S adults hospitalized with COVID-19
finds that, overall, patients taking immunosuppressive drugs do
not face increased risk of being put on a ventilator or death.



FULL STORY ==========================================================================
A large, nationwide study of COVID-19 cases led by researchers at the
Johns Hopkins Bloomberg School of Public Health has found that people
taking medications that suppress the immune system -- for example, to
prevent transplant rejection or to treat cancer -- overall do not have
a higher risk of dying from COVID-19 or being put on a ventilator than non-immunosuppressed hospitalized COVID-19 patients.


==========================================================================
The researchers analyzed electronic health records of adults
hospitalized with COVID-19 from January 2020 to June 2021, covering
222,575 individuals, including 16,494 -- 7 percent of the total cases
in the study period -- in which patients had been on immunosuppressive medications prior to hospitalization. The researchers separated these medications into 17 classes and found that none were associated with a significantly increased risk of being put on a ventilator -- an indication
of severe COVID-19 illness.

The results were published online November 15 in The Lancet Rheumatology.

"In general, people taking immunosuppressive medications may be reassured
that they can safely continue to do so during this pandemic," says study
lead author Kayte Andersen, MSc, a doctoral candidate in the Bloomberg
School's Department of Epidemiology.

"These findings are encouraging and important, given how commonly these medications are used," says G. Caleb Alexander, Professor of Epidemiology
at the Bloomberg School.

Estimates suggest that there are approximately 10 million
immunocompromised people in the U.S. People who take immunosuppressive
drugs for organ transplants, autoimmune diseases, cancers and other
conditions were considered, at the outset of the pandemic, as being
at potentially increased risk of severe outcomes, given their weakened
immune systems. On the other hand, some of the damage to lungs and other
organs in severe COVID-19 comes less from direct viral damage and more
from immune overactivation. By the summer of 2020, doctors were treating
severe COVID-19 with immunosuppressive drugs such as dexamethasone. It
was not initially clear whether the long-term use of immunosuppressive
drugs increased or decreased the risk of severe COVID-19.



==========================================================================
In a smaller, preliminary study published earlier this year, Andersen, Alexander, and their colleagues found no significant association between
the chronic use of immunosuppressive drugs and ventilator or mortality
risk - - suggesting that perhaps any increased susceptibility to infection
and viral spread may be balanced by a decreased susceptibility to harmful inflammation.

This earlier study analyzed the health records of more than 2,000
hospitalized COVID-19 patients from the Johns Hopkins Medicine network.

The new study, drawing from a nationwide dataset gathered by the National
COVID Cohort Collaborative, covered a sample of COVID-19 patients that
was over 100 times larger than the preliminary study. The study found
that overall, hospitalized COVID-19 patients taking immunosuppressive
drugs did not face significant increases in the risk of COVID-19 death
compared with non- immunosuppressed hospitalized COVID-19 patients.

Of the 303 drugs examined in the study, the authors found that
one drug, rituximab, a monoclonal antibody preparation that targets antibody-producing B cells, was associated with a substantially increased
risk of death compared to medically similar hospitalized COVID-19
patients. Rituximab is used for serious medical conditions like cancer
or an autoimmune disorder that has not responded to other treatments.

The analysis included 153 cancer patients taking rituximab and 100
patients taking rituximab for a rheumatologic condition. After accounting
for sex, age, medical conditions, and other factors, the risk of death for
the cancer patients taking rituximab was more than double and the risk
for patients with a rheumatologic condition was nearly three-quarters
higher compared with medically similar people in the study.

"Given the finding, patients taking rituximab should discuss their
options with their doctor," says Andersen. "At a minimum, people who
take rituximab should continue to protect themselves from developing
COVID-19. It also makes it all the more important that people around
those taking rituximab get vaccinated." A commentary accompanying the
paper in The Lancet Rheumatology discusses the rituximab finding and
suggests two potential paths for patients and clinicians -- proceeding
with rituximab or using alternative therapies.

Andersen and colleagues' analysis also linked a relatively new class of immunosuppressive drugs called JAK inhibitors, which are used to treat arthritis, inflammatory bowel disease, and other inflammatory conditions,
to a significantly lower risk -- 58 percent -- of COVID-19-related
in-hospital death. JAK inhibitors such as baricitinib have recently been
used to treat severe COVID-19.

"Long-term Use of Immunosuppressive Medicines and In-Hospital COVID-19 Outcomes: a Retrospective Cohort Study Using Data from the National
COVID Cohort Collaborative" was co-authored by Kathleen M. Andersen,
Benjamin Bates, Emaan Rashidi, Amy Olex, Roslyn Mannon, Rena Patel,
Jasvinder Singh, Jing Sun, Paul Auwaerter, Derek Ng, Jodi Segal, Brian Garibaldi, Hemalkumar Mehta, and G.

Caleb Alexander.

Andersen received doctoral training support from the National Heart,
Lung and Blood Institute Pharmacoepidemiology T32 Training Program (T32HL139426).

========================================================================== Story Source: Materials provided by Johns_Hopkins_University_Bloomberg_School_of_Public Health. Note:
Content may be edited for style and length.


========================================================================== Journal Reference:
1. Kathleen M Andersen, Benjamin A Bates, Emaan S Rashidi, Amy L Olex,
Roslyn B Mannon, Rena C Patel, Jasvinder Singh, Jing Sun, Paul G
Auwaerter, Derek K Ng, Jodi B Segal, Brian T Garibaldi, Hemalkumar
B Mehta, G Caleb Alexander, Melissa A Haendel, Christopher G
Chute. Long- term use of immunosuppressive medicines and in-hospital
COVID-19 outcomes: a retrospective cohort study using data from
the National COVID Cohort Collaborative. The Lancet Rheumatology,
2021; DOI: 10.1016/S2665- 9913(21)00325-8 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/11/211116175040.htm

--- up 5 days, 2 hours, 55 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)